Self-management programs that include cognitive behavioral strategies have been shown to improve gastrointestinal (GI) symptoms, psychological distress, and quality of life (QoL) in persons with irritable bowel syndrome (IBS). However, less is known about the physiological impact of such a change. As part of a randomized controlled trial using a comprehensive self-management (CSM) intervention (n ¼ 126) compared to usual care (UC; n ¼ 62), cortisol levels were measured in 4 weekly first morning urine samples at baseline and at 3-, 6-, and 12-month follow-up. In addition, diary (28 days) ratings of stress were recorded at baseline, 3, 6, and 12 months. The omnibus test of all three outcome times showed no differences in urine cortisol levels between the CSM and UC groups (p ¼ .400); however, at 3 months the CSM group had significantly higher cortisol levels than the UC group (p ¼ .012). The CSM group reported lower daily stress levels (p ¼ .046 from the omnibus test of all 3 time points) than the UC group, with the effect getting stronger over time. Despite marked improvements in reported stress and previously reported GI and psychological distress symptoms at later follow-ups, the CSM program did not reduce urine cortisol levels in adults with IBS. These results suggest that the first-void urine cortisol levels are not reflective of self-reported daily stress in this patient population.
Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder that is defined by recurring abdominal pain/ discomfort that is relieved by a bowel movement or associated with changes in stool frequency or consistency (Drossman et al., 2006) . IBS affects approximately 5-15% of the population worldwide (F. Y. Chang & Lu, 2007; Drossman, Corazziari, Talley, Thompson, & Whitehead, 2000; Gwee, Wee, Wong, & Png, 2004; Hungin, Whorwell, Tack, & Mearin, 2003) and twice as many women are diagnosed with IBS than men (L. Chang, Toner, et al., 2006; Voci & Cramer, 2009) . Patients with IBS demonstrate high health care utilization. As a result, IBS has a significant impact on health care costs in terms of both diagnosis and treatment as well as individual patients' quality of life (QoL; Brun-Strang, Dapoigny, Lafuma, Wainsten, & Fagnani, 2007; Nyrop et al., 2007) .
Alterations in central processing of afferent input from the GI tract may contribute to the pathophysiology of IBS (Ballenger et al., 2001; Mulak & Bonaz, 2004) . Several studies support the conjecture that patients with IBS have increased levels of psychological distress (e.g., anxiety, depression); moreover, psychological distress and feeling stressed have been associated with symptom onset or exacerbation (Drossman et al., 1999; Hertig, Cain, Jarrett, Burr, & Heitkemper, 2007; Mayer, Craske, & Naliboff, 2001) . Similar to previous studies by Levy, Cain, Jarrett, and Heitkemper (1997) and Suls, Wan, and Blanchard (1994) , Blanchard et al. (2008) found no significant difference between IBS and non-IBS patients on retrospective report of major life events.
There are several pharmacologic and nonpharmacologic treatments available for IBS (Drossman et al., 2003; Lackner et al., 2008; Lackner, Mesmer, Morley, Dowzer, & Hamilton, 2004) . Nevertheless, more than two thirds of IBS patients using a large (n ¼ 1966) Internet survey reported dissatisfaction with the medications they currently use to treat their IBS symptoms (Drossman et al., 2009) . A number of additional pharmacologic and nonpharmacologic treatments are currently undergoing development and preliminary testing. Over the last two decades, several nonpharmacological intervention studies have achieved improved GI symptoms, psychological distress, and QoL in patients with IBS (Drossman et al., 2003; Lackner et al., 2010; Whitehead et al., 2004) , including a comprehensive self-management (CSM) program our team developed (Heitkemper et al., 2004; Jarrett et al., 2009) . In our study, we also found a trend toward decreased urine cortisol levels in young women with IBS in the intervention group as compared with the usual care (UC) group (Heitkemper et al., 2004) . However, we could find no studies that examined the impact of a behavioral intervention on indicators of hypothalamicpituitary-adrenal (HPA) axis activity in concert with the report of daily stress in women and men with IBS.
The aims of the current analysis described below were (a) to test the effect of a CSM intervention on urine cortisol and daily stress levels at 3-, 6-, and 12-month follow-ups compared to a UC group in adults with IBS; (b) to explore gender differences in urine cortisol levels and daily stress reports at baseline assessment in adults with IBS; and (c) to test whether the intervention effectiveness differed in women versus men. We hypothesized that (a) participants in the CSM group would demonstrate greater reductions in cortisol and daily stress levels at 3-, 6-, and 12-month follow-ups as compared with the UC group and (b) the intervention would have a stronger effect on women than on men.
Background

Gender Differences in IBS
Gender differences in coping styles and resources may explain the higher occurrence of IBS symptoms and prevalence of this syndrome in women as compared to men (Adeyemo, Spiegel, & Chang, 2010; Lund & Lundeberg, 2008; Rao, 2009) . How sex (i.e., ovarian hormones) and/or gender (i.e., social role) contribute to the female predominance in IBS is unknown. Several potential physiologic factors-for example, visceral sensitivity, GI motility, and autonomic nervous system homeostasis-may contribute to gender differences in IBS symptoms (L. Chang, Mayer, et al., 2006; Heitkemper & Jarrett, 2008; Lund & Lundeberg, 2008; Schmulson et al., 2010) . Women with IBS report greater psychological distress as well as lower health-related QoL than men with IBS (L. Chang, Toner, et al., 2006) . Additional factors such as gender role may contribute to gender differences in QoL and psychological adjustment to a chronic, intermittent health condition (Farnam, Somi, Sarami, & Farhang, 2008; Voci & Cramer, 2009 ).
Cortisol and Psychological Stress
Psychological, cognitive, and emotional stressors activate the HPA axis in the central nervous system (Pruessner et al., 2010) , resulting in the release of corticotropin releasing factor (CRF) from the hypothalamus. CRF stimulates the release of adrenocorticotropin hormone (ACTH) from the anterior pituitary and, ultimately, cortisol from the adrenal cortex. Researchers have used cortisol level as a physiologic indicator of neuroendocrine and psychological responses to stress in groups of patients with chronic disorders such as IBS (Burr, Jarrett, Cain, Jun, & Heitkemper, 2009; L. Chang et al., 2009; FitzGerald, Kehoe, & Sinha, 2009) , chronic fatigue syndrome (Roberts, Papadopoulos, Wessely, Chalder, & Cleare, 2009) , and posttraumatic stress disorder (PTSD; Yehuda et al., 2009 ). In addition, investigators have used cortisol as an objective marker to confirm data reported in questionnaires (Pruessner, Hellhammer, Pruessner, & Lupien, 2003) and improvement following stress reduction programs in various chronic medical conditions (Matousek, Dobkin, & Pruessner, 2010) . Pruessner et al. (2003) reported a positive association between free salivary cortisol response after awakening and self-reported severity of depression and stress levels in young male college students. In a recent review in patients with various chronic illnesses, Matousek et al. (2010) noted that cortisol is a good candidate as a marker to assess the effectiveness of mindfulness meditation practice when investigators use a rigorous methodology such as repeated measurement of salivary cortisol levels after awakening.
A number of studies have demonstrated that acute or chronic physical and psychological stressors modulate GI motor and sensory functions in patients with IBS (Dickhaus et al., 2003; Monnikes et al., 2001; Murray et al., 2004; Posserud et al., 2004) . The role of the HPA axis in IBS is less well described. HPA axis dysregulation occurs in some IBS patients (Bohmelt, Nater, Franke, Hellhammer, & Ehlert, 2005; L. Chang et al., 2009; Dinan et al., 2006; FitzGerald et al., 2009) . For example, women with IBS had higher unstimulated 24-hr plasma and first morning-void urine cortisol levels than healthy control and IBS nonpatients (L. Chang et al., 2009; Heitkemper et al., 1996) . However, others have failed to show IBS versus control differences under stimulated stress conditions (e.g., public speaking and mental stress tests; Elsenbruch et al., 2006; Posserud et al., 2004) . The discrepancy in cortisol levels may be due to type of specimen collection (i.e., blood, urine, or saliva). In plasma, cortisol is 95% protein-bound and 5% free (active) forms. Urine and saliva contain only the free form of cortisol. Blood draw may be stressful for participants, thus limiting its use as a repeated measure of stress. While 24-hr urine collection may provide useful information on total cortisol secretion, it can be challenging for participants to comply with collection procedures. Another approach is to examine overnight urine cortisol (first-voided urine) levels. Other investigators have used overnight cortisol in studies of stress and symptoms in a sample of women during the transition from premenopause to postmenopause (Woods & Mitchell, 2010) . We utilized this approach in a prior sample of menstruating women and found that women with IBS had higher overnight urine cortisol levels as compared to IBS nonpatients and controls (Heitkemper et al., 1996) .
Materials and Methods Design
The present study was a secondary data analysis of data collected during the randomized controlled trial study Nursing Management of Irritable Bowel Syndrome: Improving Outcomes, conducted between 2004 and 2008 ). We used a three-arm design to test the efficacy of a CSM intervention delivered entirely in person (CSM-IP) or predominantly by telephone (CSM-T/IP) as compared with UC. All three groups completed interviews, questionnaires, and kept daily health diaries at baseline and each of three follow-up assessment periods (at 3, 6, and 12 months postrandomization). We collected 4 weekly first morning urine samples to determine cortisol and creatinine levels at baseline and at followup by instructing participants to collect urine first thing upon arising prior to drinking or eating. To control for urine concentration, we divided cortisol levels by urine creatinine levels. A more detailed description of study design was published previously ).
Sample
We recruited the majority of participants through community advertisements. The remainder responded to letters mailed to patients attending a university-based gastroenterology clinic. To be eligible for the study, participants had to be 18-70 years of age and have a medical diagnosis of IBS and reported symptoms consistent with the Rome II criteria (Drossman et al., 2000) . Individuals were excluded if they had a coexistent history of GI, renal, or gynecological pathology or surgery that might mimic IBS-type symptoms or if they were frequently taking specific medications for IBS (e.g., antidiarrheals, laxatives, or antispasmodics) that had common GI side effects or other medications that would alter cortisol levels. However, we did not exclude women on oral contraceptive pills (OCPs) or hormone replacement therapy (HRT). Participants with comorbid conditions such as severe fibromyalgia, Type I or II diabetes mellitus, infectious diseases, or symptoms of dementia were also excluded. We obtained human subjects approval through the University of Washington Institutional Review Boards (IRB) prior to the start of study recruitment ).
Measures
Demographics. Participants self-reported their age (in years), gender (woman or man), marital status (single or married), formal education level (less than or at least a baccalaureate degree), employment status (full-time, part-time, unemployed, or retired), and predominant bowel pattern (constipation, diarrhea, or alternating).
Daily stress level. To measure the daily stress level, we used a single item, stressed, out of the 26 items in the daily health diary. The diary instructed participants to ''mark the highest severity that you experienced with each symptom over the past 24 hr'' on a 5-point Likert-type scale, with 0 ¼ not present, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe, and 4 ¼ very severe. We computed the overall stress level by collapsing the 28 days of diary for each participant to determine the percentage of days with moderate-to-very severe stress.
Urine cortisol levels. We quantified cortisol levels by radioimmunoassay with the Coat-A-Count kit developed by Diagnostic Products Corporation (Los Angeles, CA), which involves dichloromethane extraction of steroids. We added aliquots of sample to tubes coated with antibodies against cortisol, exposed them to 125-iodinated cortisol, and counted them in a Packard gamma counter (Cobra II, Downers Grove, IL). We performed assays on duplicate samples and standards. The cortisol detection limit was 0.3 mg/dl and there was low crossreactivity with other steroids. The intraassay and interassay variations were 4.8% and 8.8%, respectively.
Urine creatinine levels. We relied on Jaffe's reaction to measure creatinine levels, wherein a yellow/orange color forms when the metabolite is treated with alkaline picrate. The color derived from creatinine present in the urine was then destroyed at acidic pH. We used a spectrophotometer/plate reader (Molecular Devices Corporation, Sunnyvale, CA) to detect the differences in color before and after acidification at 500 nm. We determined the creatinine concentration using a creatinine standard curve. We performed the assays on duplicate samples and standards. The intraassay and interassay variations were 1.9% and 8.5%, respectively.
Statistical Analysis
For the purpose of this study, we combined the data of CSM-IP and CSM-T/IP to one CSM group based on prior comparisons that showed no differences in the outcomes . The primary aim of this study was to test whether participants in the CSM intervention group had lower urine cortisol levels and reported lower stress levels than those in the UC group. Urine cortisol levels and percentage of days with moderate-to-very severe stress levels were the primary outcome measures. We expressed the cortisol level in ng per mg creatinine and used log 10 transformation to reduce the skewness of the cortisol levels. We computed the intraclass correlation coefficient (ICC) for reliability across the four baseline urine cortisol levels within persons. For all samples, the combined ICCs were 0.23 for untransformed and 0.34 for log 10 transformed cortisol levels. Further, we dropped urine samples with creatinine levels less than 100 mg/dl because a low creatinine level indicates diluted urine (Arndt, 2009) , which may mean that urine did not represent the full night urine or first morning void. The ICC improved to 0.39 for untransformed and 0.36 for log 10 transformed cortisol levels. We computed change scores from baseline to all follow-up times.
We performed the primary outcome analyses using mixed model analysis of covariance (ANCOVA). Each model contains intervention group (CSM vs. UC) and three follow-up occasions (3, 6, and 12 months postrandomization) as fixed factors, participant number as a random factor, and baseline values of the outcome measure, age, and gender as covariates. The primary outcomes are changes from baseline to all three follow-up periods on cortisol levels and percentage of days with moderate-to-very severe stress levels. The coefficient on intervention group measures how much the CSM group differs from the UC group at the three follow-up times, on average, and the corresponding p value tests whether this difference is statistically significant. In addition to this omnibus test, we used ANCOVA in separate analyses for each follow-up time point (3, 6, and 12 months postrandomization). With this sample size, the power analysis showed that at each time point there was 80% power for detecting a difference of 0.15 on log 10 of cortisol levels and 11-point differences on the stress level scale.
The second aim was to explore gender differences on urine cortisol and self-reported daily stress levels at baseline assessment. We used analysis of variance (ANOVA) to analyze cortisol and percentage of days with moderate-to-very severe stress levels in women and men with IBS at baseline. We accepted a p value of < .05 as the level of significance.
The third aim was to test whether intervention effectiveness differed between women and men. We used a mixed model ANCOVA to analyze the change in cortisol and percentage of days with moderate-to-very severe stress levels from baseline to all three follow-up periods. The coefficient for the gender by group interaction measures how much the treatment effect differs between women and men at the three follow-up times, on average, and the corresponding p value tests whether this difference is statistically significant at p value < .05. In addition, we used ANCOVA in separate analyses on each follow-up time point (3, 6, and 12 months postrandomization).
Results
Sample Description
We randomized participants to one of the two CSM groups (n ¼ 126) or the UC group (n ¼ 62). The demographics are described elsewhere . Mean age of the patients was 44 + 14 years. The majority of the patients were women, Caucasian, and relatively well educated. The demographic data did not differ significantly between the CSM and UC groups.
At baseline, 143 women and 31 men provided urine for cortisol/creatinine data and 161 women and 26 men provided self-reported percentage of days with moderate-to-very severe stress levels. The baseline sample sizes apply to Aim 2 analysis. Results for Aims 1 and 3 are based on participants who provided outcome data on at least one of the follow-up occasions (at 3, 6, and 12 months postrandomization). Postintervention of 90 women and 15 men provided the data for urine cortisol/creatinine levels and 140 women and 20 men provided data for percentage of days with moderate-to-very severe stress levels. Of the women, 27 were taking OCPs or receiving HRT. Table 1 shows that log 10 of urine cortisol levels were not significantly different at baseline between CSM and UC groups. The mixed model ANCOVA demonstrated a nonsignificant main effect of CSM on log 10 of urine cortisol level changes from baseline to each follow-up period as well as no interaction effect between CSM and time (p ¼ .400 and .287). Further examination of each follow-up time point showed that log 10 of urine cortisol levels decreased from baseline to 3-month follow-up in the UC group but increased in the CSM group (p ¼ .012) after controlling for covariates. However, there were no group differences at the 6-and 12-month follow-ups. These results are further illustrated in Figure 1 . The graph shows an increasing trend on cortisol levels in the UC group toward the end of follow-up period as compared to the CSM group. The mixed model ANCOVA demonstrated significant selfreported daily stress changes from baseline, as well as an interaction effect between CSM and time (p ¼ .046 and .034). The percentage of days with moderate-to-very severe stress at 6 and 12 months decreased more in the CSM group than in the UC group (p ¼ .056 and p ¼ .009, respectively). These results are further depicted in Figure 2 . The graph shows a significantly greater reduction in daily stress levels in the CSM group as compared to the UC group at follow-up points. Excluding women who were using OCPs or HRT did not substantially change the results of urine cortisol and stress levels. Figure 3 illustrates the mean of log 10 of urine cortisol levels at baseline in women and men with IBS. In this analysis, women with IBS had higher mean cortisol levels than men prior to the intervention (M ¼ 1.44, SD ¼ 0.21 vs. M ¼ 1.37, SD ¼ 0.20 ng/mg creatinine, respectively, p ¼ .087), but this difference was not statistically significant. After controlling for creatinine and age, there was no significant gender difference on cortisol levels at baseline (p ¼ .275). When we compared the percentage of days with moderate-to-very severe stress levels at baseline, women had higher but not significantly different stress levels compared to men (M ¼ 25.6, SD ¼ 23.4, M ¼ 22.0, SD ¼ 27.3, respectively, p ¼ .463). Table 2 demonstrates means (SDs) of baseline and change scores in log 10 of urine cortisol and percentage of days with moderate-to-very severe stress levels in women and men with IBS by intervention. The mixed model analysis across the three follow-up points showed nonsignificant interactions between intervention and group for both cortisol (p ¼ .175) and stress (p ¼ .277). Analyses of individual time points showed a marginally significant interaction for stress at 3-months followup (p ¼ .043).
Intervention Effect on Cortisol and Stress Levels
Gender Differences in Cortisol and Stress Levels
Discussion
The purpose of this study was to determine the effects of a CSM intervention on both urine cortisol levels and self-report of daily stress in patients with IBS. The findings of this study indicate that despite improvement in self-report of daily stress, the intervention did not lead to a reduction in first-void urine cortisol levels.
In the current study, we quantified stress with the use of the single daily-diary item ''stressed.'' In an earlier study, we reported that 23 women with GI symptoms typical of IBS but without a diagnosis of IBS had significantly higher daily stress levels (M ¼ 1.9, SD ¼ 0.7) than 26 healthy women (M ¼ 1.4, SD ¼ 0.6, p ¼ .030; Levy et al., 1997) . Women with diagnosed IBS also had higher levels of daily stress (M ¼ 1.8, SD ¼ 0.7), but their levels were not significantly different than those of the healthy comparison group. In a subsequent comparison in another population, we found that women with IBS had significantly higher levels of daily stress when compared to women without IBS. In that study, IBS women reported stress due to parental role, relationships with others, and work or school (Hertig et al., 2007) . Similarly, Whitehead, Crowell, Robinson, Heller, and Schuster (1992) reported that 39 women Figure 3 . Mean (95% confidence interval [CI]) of log 10 of cortisol levels (ng/mg creatinine) at baseline in women and men. We found no significant difference after controlling for baseline creatinine and age.
with IBS had significantly more stressful events and more severe ratings of those events than 232 normal comparison women and 108 women with other functional bowel diseases when assessed every 3 months over a 1-year period.
Other studies of cognitive behavioral therapy (CBT) in IBS patients have not examined daily self-reported stress as an outcome measure. Although GI symptoms decreased at 3 and 6 months in the current study population ), self-reported stress only began to decrease at 6 months and then persisted to 12 months, suggesting that the link between stress and abdominal symptoms in IBS may not be as straightforward as originally thought. It may be that patients with IBS receiving CBT deal better with their stress and modify their lifestyle accordingly over time.
The findings of a positive effect on self-report of stress following a cognitively focused CSM intervention without a change in cortisol levels are comparable to those of a study in 24 men with coronary artery disease (CAD; Ryden, Hedback, & Jonasson, 2009 ). Using a pretest-posttest design, Ryden et al. (2009) found that stress management behavioral therapy delivered in 20 sessions over a 1-year period failed to produce decreases in salivary cortisol despite decreases in everyday self-reported stress. The use of biobehavioral indices of improvement in patients with IBS has received little attention. Heymann- Monnikes et al. (2000) tested a 10-week CBT intervention on QoL and laboratory rectal visceral sensitivity as measured with the barostat. Despite improvements in QoL as measured at 3-and 6-month follow-up, there were no differences in rectal sensitivity, indicating improvements in the subjective but not the physiologic measure. Such findings, albeit limited with regard to IBS patients, suggest that current biomarkers of visceral sensitivity and overnight cortisol levels may not be sensitive enough to reflect self-report of stress and QoL. Other investigators using different patient populations have utilized cortisol as a marker of stress in conjunction with self-report of stress levels following a variety of stress-reducing interventions (Galvin, Benson, Deckro, Fricchione, & Dusek, 2006; Matousek et al., 2010; Walton, Pugh, Gelderloos, & Macrae, 1995; Yehuda et al., 2009) . Again, despite consistent improvements in self-reported stress or QoL with these interventions, there is less certainty as to whether there is a concomitant impact on the HPA axis. Regardless of the duration, stress reduction programs do elicit similar positive psychological effects but with inconsistent changes in physiological measures (Cummins & Gevirtz, 1993; Hansen, Garde, Skovgaard, & Christensen, 2001) .
The present analysis began with the conjectures that the stress of IBS would lead to increased cortisol in IBS patients and that CSM would lead to stress reduction and hence lowered cortisol. However, the literature relating to these conjectures is conflicting. Four studies have measured basal cortisol levels in patients with IBS. L. Chang et al. (2009) found significantly lower basal plasma ACTH levels and slightly higher basal plasma cortisol levels in young women with IBS as compared with healthy control women. Additionally, the investigators reported a significant positive correlation of plasma cortisol levels with anxiety symptoms rather than IBS symptoms (e.g., abdominal pain and bowel pattern) prior to a visceral stimulus. Similarly, in our prior study with a separate sample (Heitkemper et al., 1996) , we found higher basal afternoon urine cortisol levels in women with IBS as compared to those of IBS nonpatients (symptoms of IBS but no diagnosis) and healthy controls. On the contrary, Bohmelt et al. (2005) found significantly lower salivary cortisol levels after awakening in patients with IBS as compared to controls. In a recently published study (Heitkemper, Cain, Burr, Jun, & Jarrett, 2010) , using a separate sample from that reported here, we found lower first morning urine cortisol in women with IBS compared to women without IBS. There has also been conflicting evidence on the response to an acute stressor in persons with IBS compared to healthy controls. For instance, researchers have shown a blunted cortisol response in IBS patients exposed to corticotropin-releasing hormone (CRH; Bohmelt et al., 2005) and lumbar puncture (FitzGerald et al., 2009) ; however, L. Chang et al. (2009) found an increased cortisol response to sigmoidoscopy among persons with IBS. Inconsistent observations may be due to different participant characteristics (e.g., length of time since diagnosis), environments, specimen collection (e.g., plasma, urine, or saliva; spot or serial), time of specimen collection, and study designs. In the current study, we found significantly higher cortisol levels at 3 months postrandomization in the CSM group as compared to the UC group. This could be a spurious result due to the multiple comparisons we performed or it could be a real effect, with an initial low cortisol and the increase in cortisol at 3 months representing improved regulation of the HPA axis, which is increased to normal. Given the lack of data on the normal range for first morning urine cortisol among healthy people, it is not possible to tell whether the participants with IBS had baseline urine cortisol levels that were higher or lower than normal. Other investigators have found increased cortisol in response to psychological interventions. For example, in a longitudinal psychotherapeutic intervention study in 28 survivors of the World Trade Center attacks with PTSD, investigators found increased 24-hr urine cortisol levels in those who significantly improved their PTSD and depression severity as compared with those who did not improve, at both posttreatment and at the 3-month follow-up (Yehuda et al., 2009) . In another study, Roberts et al. (2009) reported significantly increased (p < .05) daily salivary cortisol levels following a 15-session CBT in patients with chronic fatigue syndrome. However, in that study, salivary cortisol levels did not differ between those who responded and those who did not respond to the therapy. Thus, the increase in overnight urine cortisol levels in our study at 3 months is somewhat consistent with findings in other populations following a cognitive intervention.
To our knowledge, this is the first self-management intervention study of gender differences and cortisol levels in concert with self-report of daily stress levels in patients with IBS. Women with IBS are more likely to have other coexisting health problems (fatigue, sleep disturbances; Cain et al., 2009 ) as well as psychological distress (depression) and poorer QoL than men (L. Chang, Toner, et al., 2006) . We found slightly higher urine cortisol and self-reported stress levels in women with IBS relative to men at baseline. However, this difference was not significant after controlling for creatinine and age.
As compared to men, women with IBS in both the CSM and UC groups were more likely to report a greater reduction in daily stress postintervention. In addition, women in the CSM group had greater change scores in self-reported stress levels than those in the UC group. In another study, women with IBS were more likely to change dietary habits following a dietary intervention as compared to men (Faresjo, Johansson, Faresjo, Roos, & Hallert, 2010) . In IBS, male versus female differences may be due to differences in coping style, in levels of somatic and psychological symptoms, or in health seeking patterns (Hungin, Chang, Locke, Dennis, & Barghout, 2005) . A number of authors have addressed gender-related differences in IBS in published reviews L. Chang, Toner, et al., 2006; Farnam et al., 2008) . In one study of 200 women and 50 men with IBS in Great Britain, authors reported that women had higher response rate and overall improvement post hypnotherapy relative to men, and men demonstrated a lower long-term improvement in IBS symptoms following the treatment than women (Gonsalkorale, Miller, Afzal, & Whorwell, 2003) .
The current study has several limitations. First, we used an existing data set that had a relatively small number of men. Second, there was no healthy non-IBS control group to compare the overnight cortisol levels in first-voided urine with those of the intervention groups. A one-time urine collection after awakening may not adequately reflect HPA axis activity. Third, we were unable to verify participant compliance with the desired protocol for urine collection. Although we instructed participants on the importance of following the study protocol, we did not ask them to report the collection time. Thus, it is possible that the samples were not the first morning-voided urine. We eliminated samples in which the urine creatinine values were less than 100 mg/dl because of concerns that they may not have been representative of overnight values (Arndt, 2009) . Also, urine collection may be a burden for participants. Salivary cortisol levels have been used in many studies related to HPA axis activity Ehlert et al., 2005) , self-report stress response (Almeida, McGonagle, & King, 2009; Pruessner et al., 2003) , and intervention effect (Galvin et al., 2006; Matousek et al., 2010; Roberts et al., 2009; Ryden et al., 2009 ). The collection of saliva for cortisol levels is less burdensome for the participants as compared to blood or urine. Therefore, the utility of using repeated measures of salivary cortisol remains to be explored in intervention trials in patients with IBS.
In conclusion, the CSM program shows effectiveness in reducing self-report of daily stress but no effect on reducing morning urine cortisol level as compared with the UC over time. There is no evidence of a differential effect of treatment on women compared to men; however, the sample size of men is small, meaning the power of this comparison is low.
